04-9527. Delegation of Authority  

  • Start Preamble

    Notice is hereby given that I have delegated to Commissioner Food and Drugs, the authority vested in the Secretary of the Department of Health and Human Services, under Section 353 of the Public Health Service Act (42 U.S.C. 263a), as amended, to implement CLIA's complexity categorization provisions as they apply to commercially available tests to the Commissioner of Food and Drugs (FDA). This authority includes, but is not limited to the following:

    (a) Interpreting the CLIA provisions related to complexity categorization;

    (b) Holding public workshops and meetings on CLIA complexity categorization; and,

    (c) Developing and issuing implementing rules and guidance for CLIA complexity categorization.

    The Administrator of the Centers for Medicare & Medicaid Services (CMS) will provide funding to implement CLIA's complexity categorization provisions as set forth in the Agency Agreement between FDA and CMS (CMS IA-04-01, FDA 224-04-6052), as amended.

    Except as provided above, the existing delegation of authority to the Administrator of CMS concerning CLIA is unaffected.

    This delegation supersedes the delegation of authority memorandum dated October 31, 2003, from the Secretary to the Commissioner of Food and Drugs, titled “Delegation of Authority for the Clinical Laboratory Improvements Amendments of 1988 (CLIA), Section 353 of the Public Health Service Act, as amended.”

    This delegation shall be exercised under the Department's existing delegation and policy on regulations. In addition, I ratified and reaffirmed any actions taken by you or your subordinates which involved the exercise of this authorities prior to the effective date of this delegation.

    This delegation was effective upon date of signature.

    Start Signature

    Tommy G. Thompson,

    Secretary, Department of Health and Human Services

    End Signature End Preamble

    [FR Doc. 04-9527 Filed 4-26-04; 8:45 am]

    BILLING CODE 4160-01-M

Document Information

Published:
04/27/2004
Department:
Food and Drug Administration
Entry Type:
Notice
Document Number:
04-9527
Pages:
22849-22849 (1 pages)
PDF File:
04-9527.pdf